Fernando de Castro

MIF-induced CD74+ microglia/macrophages are clinically relevant disease-associated subpopulations in brain metastasis and other CNS disorders

The paper identifies CD74+ microglia/macrophages driven by MIF as clinically relevant subpopulations in brain metastasis and other CNS disorders, showing their role in disease progression and therapeutic targeting potential.

TAF1-dependent transcriptional dysregulation underlies multiple sclerosis

This study identifies TAF1-dependent transcriptional dysregulation as a mechanism underlying multiple sclerosis progression and presents an in vivo model for therapeutic development.

ApTOLL, a new therapeutic aptamer for cytoprotection and (re)myelination after Multiple Sclerosis.

ApTOLL, an aptamer targeting TLR4, shows immunomodulatory and remyelinating effects in MS models and cell cultures.

Activation of Shh/Smo is sufficient to maintain oligodendrocyte precursor cells in an undifferentiated state but is not necessary for differentiation

This study shows that Shh/Smo activation maintains oligodendrocyte precursor cells (OPCs) in an undifferentiated state but is not required for myelination or remyelination.

Extracellular matrix protein anosmin-1 overexpression regulates dopaminergic phenotype in the CNS and the PNS with no pathogenic consequences in MPTP model of Parkinson disease

This study shows that overexpression of anosmin-1 increases dopaminergic neurons and alters striatum organization but does not affect susceptibility to MPTP-induced Parkinsonism.

Dynamics of central remyelination and treatment evolution in a model of Multiple Sclerosis with Optic Coherence Tomography

This study uses optical coherence tomography to monitor remyelination in MS patients and validates the therapeutic potential of VP3.15 as a remyelinating drug.

Age-linked heterogeneity among oligodendrocyte precursor cells in the cerebral cortex of mice and human

This study examines age-related differences in oligodendrocyte precursor cells (OPCs) from mice and humans, showing distinct metabolic patterns and responses to FGF2 and anosmin-1 across developmental stages.